Fundraising of 700 Million Yen from Fiducia and Yokohama Capital

Innovacell K.K. (headquartered in Shibuya, Tokyo, with CEOs Colin Lee Novick and Jason David Sieger) aims to improve people’s health and quality of life through cell therapy for the treatment of fecal and urinary incontinence. We are pleased to announce that in April 2022, we received a total investment of 700 million yen from Fiducia Co., Ltd.’s Fiducia GrowthTech Limited Liability Partnership, which focuses on growth-stage Japanese companies with advanced technology, and the Kibou Fund from Yokohama Capital, which actively invests in small and medium-sized enterprises in growth sectors.

I am delighted to announce our first fundraising since taking office. Our company aims to swiftly deliver new treatment options to patients suffering from fecal and urinary incontinence, and we are currently in the process of launching our Phase III international joint clinical trial.

As a Japanese company, our immediate goal is to quickly provide our cell therapy to patients in Japan and Europe, followed by gaining approval in the United States and achieving global growth. The investments from Fiducia GrowthTech Investment Limited Partnership, which has the founding principle of “bridging technology companies to global success,” and the Kibou Fund from Yokohama Capital, which supports small and medium enterprises in growth sectors, are incredibly meaningful to us.

I would like to take this opportunity to express my gratitude to both new and existing shareholders for their deep understanding and support of our mission and strategy.